The Chiang Mai site for the MTN-035 rectal microbicide study has been activated.

MTN is excited to report that the Chiang Mai, Thailand site for the MTN-035 rectal microbicide study has been activated.  MTN-035, or DESIRE (Developing and Evaluating Short-acting Innovations for Rectal Use), is the first study to systematically examine placebo methods for delivering drugs to help prevent HIV from receptive anal sex.  Study participants are using three placebo products rectally – a douche, suppository and insert (fast-dissolving tablet inserted into the rectum).